Aripiprazole

Pre-clinicalTerminated
0 watching 0 views this week๐Ÿ’ค Quiet
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tourette's Syndrome

Conditions

Tourette's Syndrome

Trial Timeline

Jan 1, 2004 โ†’ Oct 1, 2006

About Aripiprazole

Aripiprazole is a pre-clinical stage product being developed by Bristol Myers Squibb for Tourette's Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT00282139. Target conditions include Tourette's Syndrome.

Hype Score Breakdown

Clinical
5
Activity
2
Company
9
Novelty
2
Community
1

Clinical Trials (20)

NCT IDPhaseStatus
NCT01386086Phase 3Completed
NCT00665444Pre-clinicalTerminated
NCT00308074Phase 2Completed
NCT00619190Phase 2Completed
NCT00608543ApprovedCompleted
NCT00312598Pre-clinicalCompleted
NCT00221416Phase 3Completed
NCT00221962ApprovedCompleted
NCT00209027Pre-clinicalTerminated
NCT00438386ApprovedCompleted
NCT00374348Pre-clinicalCompleted
NCT00208169ApprovedCompleted
NCT00220636ApprovedCompleted
NCT00198055Phase 2Completed
NCT00250705ApprovedCompleted
NCT00222833ApprovedCompleted
NCT00223496ApprovedCompleted
NCT00226317Pre-clinicalCompleted
NCT00194038ApprovedCompleted
NCT00224822ApprovedCompleted

Competing Products

2 competing products in Tourette's Syndrome

See all competitors
ProductCompanyStageHype Score
PF-03654746 + Placebo + Placebo + PF-03654746PfizerPhase 2
51
Tetrabenazine MR + PlaceboBausch HealthPhase 2
47